SG11202102727RA - Immunoproteasome inhibitor formulation - Google Patents

Immunoproteasome inhibitor formulation

Info

Publication number
SG11202102727RA
SG11202102727RA SG11202102727RA SG11202102727RA SG11202102727RA SG 11202102727R A SG11202102727R A SG 11202102727RA SG 11202102727R A SG11202102727R A SG 11202102727RA SG 11202102727R A SG11202102727R A SG 11202102727RA SG 11202102727R A SG11202102727R A SG 11202102727RA
Authority
SG
Singapore
Prior art keywords
inhibitor formulation
immunoproteasome inhibitor
immunoproteasome
formulation
inhibitor
Prior art date
Application number
SG11202102727RA
Other languages
English (en)
Inventor
Evan Lewis
Original Assignee
Kezar Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kezar Life Sciences filed Critical Kezar Life Sciences
Publication of SG11202102727RA publication Critical patent/SG11202102727RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SG11202102727RA 2018-10-04 2019-10-04 Immunoproteasome inhibitor formulation SG11202102727RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862741221P 2018-10-04 2018-10-04
PCT/US2019/054605 WO2020072848A1 (en) 2018-10-04 2019-10-04 Immunoproteasome inhibitor formulation

Publications (1)

Publication Number Publication Date
SG11202102727RA true SG11202102727RA (en) 2021-04-29

Family

ID=68296831

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102727RA SG11202102727RA (en) 2018-10-04 2019-10-04 Immunoproteasome inhibitor formulation

Country Status (16)

Country Link
US (1) US20220040192A1 (zh)
EP (1) EP3860574A1 (zh)
JP (1) JP2022501404A (zh)
KR (1) KR20210071982A (zh)
CN (2) CN113164397A (zh)
AU (1) AU2019355041A1 (zh)
BR (1) BR112021006339A2 (zh)
CA (1) CA3113530A1 (zh)
CL (1) CL2021000832A1 (zh)
CO (1) CO2021004990A2 (zh)
MX (1) MX2021003899A (zh)
PE (1) PE20211817A1 (zh)
PH (1) PH12021550717A1 (zh)
SG (1) SG11202102727RA (zh)
TW (1) TWI827694B (zh)
WO (1) WO2020072848A1 (zh)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
KR20170066506A (ko) * 2014-10-01 2017-06-14 메르크 파텐트 게엠베하 보론산 유도체
KR102655020B1 (ko) * 2016-06-29 2024-04-04 케자르 라이프 사이언스 펩티드 에폭시케톤 면역프로테아좀 억제제의 결정질 염

Also Published As

Publication number Publication date
KR20210071982A (ko) 2021-06-16
WO2020072848A1 (en) 2020-04-09
CN113164397A (zh) 2021-07-23
US20220040192A1 (en) 2022-02-10
PH12021550717A1 (en) 2021-11-03
CA3113530A1 (en) 2020-04-09
BR112021006339A2 (pt) 2021-07-06
JP2022501404A (ja) 2022-01-06
EP3860574A1 (en) 2021-08-11
CN116983271A (zh) 2023-11-03
CO2021004990A2 (es) 2021-04-30
PE20211817A1 (es) 2021-09-14
MX2021003899A (es) 2021-06-04
CL2021000832A1 (es) 2021-10-22
TW202027729A (zh) 2020-08-01
AU2019355041A1 (en) 2021-04-15
TWI827694B (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
IL283639A (en) kif18a inhibitors
IL278336B (en) mcl–1 inhibitors
IL277006A (en) CD73 inhibitors
PT3626699T (pt) Inibidor de ssao
IL304348A (en) cd73 inhibitors
GB201705971D0 (en) Inhibitor compounds
GB201819126D0 (en) Inhibitor compounds
IL274523A (en) Immunoproteasome inhibitors
IL276013A (en) pi4kiiibeta inhibitors
LT3571208T (lt) Imunoproteasomų slopikliai
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
SI3710457T1 (sl) Zaviralci imunoproteasoma
SG11202102727RA (en) Immunoproteasome inhibitor formulation
PL3606515T3 (pl) Preparat inhibitora STAT3
GB201809939D0 (en) Eastase inhibitor
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201819136D0 (en) Inhibitor compounds
GB201806130D0 (en) Inhibitor compounds
GB201806131D0 (en) Inhibitor compounds
EP3426641A4 (en) IMMUNOPROTEASOMINHIBITORANALOGA
GB201720145D0 (en) Inhibitor compounds
GB201708510D0 (en) Inhibitor compounds
GB201708507D0 (en) Inhibitor compounds
GB201708502D0 (en) Inhibitor compounds